Esketamine Combined With SSRI or SNRI for Treatment-Resistant Depression
In this retrospective comparative effectiveness study, among the study sample, incidence of mortality, hospitalizations, depressive relapses, and suicide attempts was low. The esketamine + SNRI group showed lower incidence of mortality, hospitalizations, and depressive relapses, while the esketamine + SSRI group showed a slightly lower incidence of suicidal attempts.
Authors
- Marina Borro (ORCID: https://orcid.org/0000-0002-7839-9125)
- Giovanna Gentile (ORCID: https://orcid.org/0000-0001-8667-3094)
- Stefano Ferracuti (ORCID: https://orcid.org/0000-0003-1150-1460)
- Jan Francesco Arena (ORCID: https://orcid.org/0000-0003-1477-2645)
- Antonio Del Casale (ORCID: https://orcid.org/0000-0003-2427-6944)
- Maurizio Simmaco (ORCID: https://orcid.org/0000-0003-4164-1472)
- Sara Spirito
- Robert Preißner (ORCID: https://orcid.org/0000-0002-2407-1087)
- Martina Nicole Modesti (ORCID: https://orcid.org/0000-0001-8540-4407)
- Saskia Preißner (ORCID: https://orcid.org/0000-0002-3672-0283)
Institutions
- Humboldt-Universität zu Berlin (DE)
- CTO Andrea Alesini (IT)
- Azienda Ospedaliera Sant'Andrea (IT)
- Freie Universität Berlin (DE)
- Charité - Universitätsmedizin Berlin (DE)
- Sapienza University of Rome (IT)
Publication Details
- Journal
- JAMA Psychiatry
- Published
- 2025-04-04
- DOI
- https://doi.org/10.1001/jamapsychiatry.2025.0200
- Citations
- 12
- Primary Topic
- Treatment of Major Depression
- Type
- article
- Field-Weighted Citation Impact
- 16.73